NEW BRUNSWICK, N.J. and LEIDEN, Netherlands, Feb. 22, 2011
/PRNewswire/ — Johnson & Johnson (NYSE:
JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq:
CRXL; Swiss Exchange: CRX) today announce that Johnson &
Johnson has completed the tender offer for Crucell N.V. (Crucell)
and has declared the offer unconditional. As a result,
Crucell will now operate as the center for vaccines within the
Johnson & Johnson pharmaceuticals group.
Reference is made to the joint press release of Johnson &
Johnson and Crucell dated 8 December 2010 announcing the
recommended cash offer by Johnson & Johnson, through its
indirect wholly-owned subsidiary JJC Acquisition Company B.V. (the
Offeror), for all of the issued and outstanding ordinary shares
(Ordinary Shares) in the capital of Crucell, including all Ordinary
Shares represented by American depositary shares (ADSs), each ADS
representing one Ordinary Share (Ordinary Shares and ADSs are
referred to herein as the Shares and the holders of such Shares are
referred to as the Shareholders) at an offer price of euro 24.75
per share (the Offer).
Johnson & Johnson will commence, through the Offeror, a
subsequent offering period to allow Shareholders who have not yet
accepted the Offer to tender their Shares, as further described
below. Johnson & Johnson encourages Shareholders who have
not yet accepted the Offer to do so immediately.
Highlights
Johnson & Johnson declares the Offer
unconditionalShare Acceptance Level is 95.24% of the
issued and outstanding share capital of CrucellSettlement of
the Offer will take place on 25 February
2011Remaining Shares can be tendered in a Subsequent
Offering Period ending 8 March 2011
O
‘/>”/>
SOURCE
